Edwards Lifesciences Corp Q4 FY2024 earnings call

Management Statement and Operational Highlights

• 2024 Performance: Edwards had strong financial performance in 2024 with sales growing 9% to $5.4 billion. Key actions included completing the sale of Critical Care, optimizing the company for agility and innovation, significant R&D investment, and strategic acquisitions (JC Medical, JenaValve, Endotronix) to expand into new therapeutic areas.
• Q4 2024: Total company sales grew 9%, ahead of expectations, with strong growth drivers including TAVR, mitral and tricuspid, structural heart failure, and aortic regurgitation. The company exited 2024 in a strong position with a solid foundation and strategic decisions in place.
• Strategic Investments: Substantial investment in R&D to augment the portfolio with new breakthrough technologies. Acquisitions provided expanded opportunities in new therapeutic areas to address unmet patient needs.
• TAVR Details: Early TAVR trial results showed superior outcomes for asymptomatic severe aortic stenosis patients, driving potential changes to the standard of care. Efforts are ongoing in the U.S. to manage capacity and in international markets to expand TAVR therapy adoption.
• TMTT Details: Strong growth in TMTT with PASCAL and EVOQUE contributing to sales. The forthcoming SAPIEN M3 mitral replacement system is expected to launch in Europe mid-2025 with U.S. approval in 2026.
• Surgical Details: Growth in the surgical product group is driven by continued adoption of the RESILIA portfolio, with evidence generation to expand global access, as seen in the KONECT study results.

Segment Performance

• TAVR: Full year 2024 global sales reached $4.1 billion, a 6% year-over-year increase. In Q4 2024, global sales were $1.04 billion, up 5.3% year-over-year. The U.S. market performed strongly with the SAPIEN platform, and international growth potential exists with continued launches and expansion in regions like Europe and Japan. Revenue contribution from TAVR is significant, and early TAVR trial results are driving potential care standard changes.
• TMTT: Full year 2024 sales were $352 million, a 77% year-over-year increase. Q4 2024 sales were $105 million. The PASCAL repair system and EVOQUE tricuspid replacement system were key contributors to growth. Revenue contribution from TMTT is growing meaningfully to the overall company performance.
• Surgical: Full year 2024 global sales were $981 million, a 6% year-over-year increase. Q4 2024 global sales were $244 million, up 5% year-over-year. Growth is driven by the premium RESILIA portfolio (INSPIRIS, MITRIS, KONECT) with healthy global adoption of these technologies.

Guidance

• 2025 Financial Outlook: Total company sales expected to be $5.6 billion to $6 billion. TAVR sales projected to be $4.1 billion to $4.4 billion, TMTT sales $500 million to $530 million, and Surgical sales $970 million to $1.05 billion. Q1 sales expected to be sequentially higher, but growth rates below the low end of full year guidance ranges initially due to factors like one less selling day and slow start to January.
• Profit Margins: 2025 adjusted gross profit margin expected to be between 78% and 79%. Operating margin guidance is 27% to 28%, with tax rate expected to be 15% to 18% excluding special items.

Risks

• Foreign Exchange: Impact on sales, with approximately $130 million or 2.5 percentage points downside expected in 2025 due to foreign exchange rate fluctuations.
• Regional Pressures: Japan and other regions face challenges, requiring enhanced capabilities to drive growth. Boston Scientific pressures in Europe were noted as transient but requiring attention.
• Regulatory: Uncertainties around the finalization of the NCD for EVOQUE and potential impact on patient access, as well as the complexity of physician and CED criteria in tricuspid NCD proposals.

Question and Answer

• Q: David Roman on TMTT performance and 2025 growth A: Discussed 2024 performance drivers (PASCAL and EVOQUE launches in U.S. and Europe) and 2025 growth expectations, noting linear growth of TMTT revenue throughout the year.
• Q: Robbie Marcus on P&L and regional pressures A: Commented on SG&A and R&D spend, expecting improvement in operating margins through management of spend levels, and discussed regional pressures on TAVR, including Japan's growth challenges.
• Q: Larry Biegelsen on EVOQUE and Early TAVR A: Shared EVOQUE patient stories highlighting life-changing outcomes, discussed NTAP impact and NCD finalization in March, and spoke about early TAVR data driving referral volume growth and the need for education and guideline changes to impact procedures.
• Other questions: Covered topics like centers growth for EVOQUE, trial timelines, Q1 guidance factors, NCD proposal impact, and early TAVR referral volume observations, with responses from company executives on enrollment, timelines, and expected impacts.